Since encorafenib is known to bind less to plasma protein compared to dabrafenib, and free drug diffuses through collagen faster than protein-bound drug, these data suggest that albumin binding may have a greater impact on limiting the transport of dabrafenib through tumor stroma, compared to encorafenib. The gene discussed is ALB; the disease is neoplasm.